These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34791262)

  • 21. Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database.
    Yamato K; Inada K; Enomoto M; Marumoto T; Takeshima M; Mishima K
    BMC Psychiatry; 2021 Jan; 21(1):40. PubMed ID: 33441086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
    Sung SC; Wisniewski SR; Luther JF; Trivedi MH; Rush AJ;
    J Affect Disord; 2015 Mar; 174():157-64. PubMed ID: 25497473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
    Pałasz A; Lapray D; Peyron C; Rojczyk-Gołębiewska E; Skowronek R; Markowski G; Czajkowska B; Krzystanek M; Wiaderkiewicz R
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):157-68. PubMed ID: 23702225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel substituted octahydropyrrolo[3,4-c]pyrroles as dual orexin receptor antagonists for insomnia treatment.
    Wu S; Sun Y; Hu Y; Zhang H; Hou L; Liu X; Li Y; He H; Luo Z; Chen Y; Wang Y; Shi W; Shen L; Cao C; Liang W; Xu Q; Lv Q; Lan J; Li J; Chen S
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1458-1462. PubMed ID: 28216404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
    Leblé N; Radon L; Rabot M; Godart N
    Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
    Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J
    Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice.
    Fava M; Rush AJ
    Psychother Psychosom; 2006; 75(3):139-53. PubMed ID: 16636629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
    Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
    Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
    Recourt K; de Boer P; Zuiker R; Luthringer R; Kent J; van der Ark P; Van Hove I; van Gerven J; Jacobs G; van Nueten L; Drevets W
    Transl Psychiatry; 2019 Oct; 9(1):240. PubMed ID: 31578318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
    Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder.
    Haghighi M; Khodakarami S; Jahangard L; Ahmadpanah M; Bajoghli H; Holsboer-Trachsler E; Brand S
    J Psychiatr Res; 2014 Nov; 58():109-14. PubMed ID: 25130678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical specificity profile for novel rapid acting antidepressant drugs.
    Scala M; Fanelli G; De Ronchi D; Serretti A; Fabbri C
    Int Clin Psychopharmacol; 2023 Sep; 38(5):297-328. PubMed ID: 37381161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
    Reeves H; Batra S; May RS; Zhang R; Dahl DC; Li X
    J Clin Psychiatry; 2008 Aug; 69(8):1228-1236. PubMed ID: 18681749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians.
    Wilt TJ; MacDonald R; Brasure M; Olson CM; Carlyle M; Fuchs E; Khawaja IS; Diem S; Koffel E; Ouellette J; Butler M; Kane RL
    Ann Intern Med; 2016 Jul; 165(2):103-12. PubMed ID: 27136278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials.
    Hausenblas HA; Saha D; Dubyak PJ; Anton SD
    J Integr Med; 2013 Nov; 11(6):377-83. PubMed ID: 24299602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.